Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702554 | 0.96 | CRBN (0.67) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23702573 | 0.95 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23702535 | 0.95 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL30376233 | 0.95 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL25189934 | 0.95 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL2384063 | 0.91 | CRBN (0.68) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL2380364 | 0.91 | CRBN (0.72) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL19662124 | 0.90 | CRBN (0.68) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL21331518 | 0.89 | CRBN (0.67) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL2382907 | 0.89 | CRBN (0.69) | CRBNDDB1EGFRHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | AURIGENE DISCOVERY TECH LTD (IN) | 2025-07-29 | — | — | US | disclosed |
| WO-2024256569-A1 | NOVEL CDK DEGRADERS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2024-12-19 | — | — | WO | disclosed |
| CN-112771038-B | Pyridazine derivatives as SMARCA2/4 degrading agents | 奥里吉恩发现科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | Aurigene Oncology Technologies Limited (IN) | 2024-08-15 | — | — | US | disclosed |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270734-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885DDB1 683/4885EGFR 3513/4885 |
| US-12371426-B2 | Pyridazine derivatives as SMARCA2/4 degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 384/4885DDB1 665/4885EGFR 3477/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885DDB1 683/4885EGFR 3513/4885 |
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | BRIX1, TP53, XPOT | CRBN 580/4885DDB1 614/4885EGFR 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.